USA As the US Inflation Reduction Act (IRA) starts to become a reality, and both big pharma and biotech companies brace themselves for its more widespread impact, BIO names Washington fixture, rare disease advocate and entrepreneur John Crowley as its new CEO. After waiting for a new leader for over…
USA In the current economic environment companies are faced with increased pressure to manage cash and meet investor expectations with tightened budgets. Life science industry CFOs, as a recent survey and webinar reveal, are looking to preserve and generate cash by making their companies more efficient and building partnerships while confronting…
USA Brad Campbell, president and COO of US rare disease specialist Amicus, talks domestic and global product launches, the company’s first steps into the gene therapy space, and how a biotech success story like Amicus can be a guiding light in market access and pricing discussions. Ultimately, we envision our…
Sweden Amicus Therapeutics is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases. Mattias Bankel, Head of Nordics and Baltics, shares his journey of establishing and developing Amicus’s presence in Sweden and other Nordic countries, furthermore his commitment to ensure that…
Serbia Predrag Lukic, general manager of Amicus, a new and exciting bridging service for MNCs looking to expand into Serbia and the Balkans, reveals the keys to accessing the region and how best to take advantage of the professional talent pool in Serbia. Through careful study of the market and by…
See our Cookie Privacy Policy Here